News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
687,917 Results
Type
Article (39150)
Company Profile (283)
Press Release (648484)
Section
Business (203902)
Career Advice (1996)
Deals (35374)
Drug Delivery (89)
Drug Development (80851)
Employer Resources (168)
FDA (16098)
Job Trends (14808)
News (344650)
Policy (32454)
Tag
Academia (2530)
Alliances (49185)
Alzheimer's disease (1257)
Approvals (16049)
Artificial intelligence (144)
Bankruptcy (352)
Best Places to Work (11581)
Biotechnology (200)
Breast cancer (188)
Cancer (1365)
Cardiovascular disease (110)
Career advice (1664)
Cell therapy (281)
Clinical research (64696)
Collaboration (482)
Compensation (260)
COVID-19 (2542)
C-suite (108)
Data (1389)
Diabetes (172)
Diagnostics (6170)
Earnings (84892)
Employer resources (146)
Events (110006)
Executive appointments (394)
FDA (16767)
Funding (426)
Gene therapy (195)
GLP-1 (597)
Government (4333)
Healthcare (18693)
Infectious disease (2634)
Inflammatory bowel disease (111)
Interviews (309)
IPO (16342)
Job creations (3625)
Job search strategy (1418)
Layoffs (418)
Legal (7861)
Lung cancer (197)
Lymphoma (98)
Manufacturing (206)
Medical device (13211)
Medtech (13216)
Mergers & acquisitions (19192)
Metabolic disorders (452)
Neuroscience (1577)
NextGen Class of 2024 (6500)
Non-profit (4467)
Northern California (1693)
Obesity (258)
Opinion (183)
Patents (117)
People (56455)
Phase I (20120)
Phase II (28496)
Phase III (21238)
Pipeline (514)
Postmarket research (2560)
Preclinical (8545)
Radiopharmaceuticals (236)
Rare diseases (259)
Real estate (5890)
Regulatory (21668)
Research institute (2311)
Resumes & cover letters (349)
Southern California (1460)
Startups (3562)
United States (15141)
Vaccines (563)
Weight loss (181)
Date
Last 7 days (580)
Last 30 days (2301)
Last 365 days (35163)
2024 (35002)
2023 (40076)
2022 (51177)
2021 (55710)
2020 (54086)
2019 (46541)
2018 (35024)
2017 (32114)
2016 (31483)
2015 (37553)
2014 (31318)
2013 (26346)
2012 (28571)
2011 (29266)
2010 (27328)
Location
Africa (713)
Arizona (195)
Asia (37286)
Australia (6087)
California (3809)
Canada (1449)
China (304)
Colorado (171)
Connecticut (176)
Europe (79824)
Florida (533)
Georgia (135)
Illinois (384)
Indiana (224)
Maryland (626)
Massachusetts (2959)
Michigan (172)
Minnesota (290)
New Jersey (1100)
New York (1080)
North Carolina (742)
Northern California (1693)
Ohio (146)
Pennsylvania (923)
South America (1091)
Southern California (1460)
Texas (547)
Utah (108)
Washington State (399)
687,917 Results for "ascletis inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Ascletis Announces Strategic Decisions on FXR agonist ASC42
Ascletis Pharma Inc. announces the strategic decisions on farnesoid X receptor agonist ASC42.
April 3, 2024
·
2 min read
Press Releases
Ascletis Completes Enrollment of Phase III Trial of ASC40 (Denifanstat) Once-Daily Oral Tablet for Treatment of Acne
November 12, 2024
·
2 min read
Press Releases
Ascletis Announces ASC47, a Muscle-Preserving Weight Loss Drug Candidate for Treatment of Obesity, in Combination with Semaglutide, Demonstrated Superior Weight Loss to Semaglutide Monotherapy in a Preclinical Model
December 18, 2024
·
11 min read
Drug Development
Ascletis Announces Dosing of the First Patient in Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. announces dosing of the first patient in Phase III clinical trial of ASC40 for treatment of moderate to severe acne vulgaris at Huashan Hospital, Fudan University.
January 24, 2024
·
2 min read
Press Releases
Ascletis Announces Promising Results from a Phase I Study in Australia for First-in-Class Muscle-Preserving Weight Loss Drug Candidate ASC47 for the Treatment of Obesity
November 8, 2024
·
10 min read
Drug Development
Ascletis Announces Poster Presentation of Phase II Study Final Results of FASN Inhibitor ASC40 for Treatment of Acne at 2024 AAD Annual Meeting
Ascletis Pharma Inc. announces the poster presentation of Phase II study final results of ASC40, a first-in-class fatty acid synthase inhibitor for treatment of acne, at the 2024 American Academy of Dermatology Annual Meeting in San Diego, the United States.
March 10, 2024
·
4 min read
Drug Development
Ascletis Announces Initiation of Phase III Clinical Trial of ASC40 (Denifanstat) for Treatment of Acne
Ascletis Pharma Inc. announces initiation of the Phase III clinical trial of fatty acid synthase inhibitor ASC40 for treatment of moderate to severe acne vulgaris.
December 5, 2023
·
4 min read
Ascletis to Participate in the Upcoming Morgan Stanley 21st Annual Global Healthcare Conference
Ascletis Pharma Inc. announces that it will participate in the upcoming Morgan Stanley 21st Annual Global Healthcare Conference.
September 4, 2023
·
1 min read
Drug Development
Ascletis Announces Poster Presentation of Phase II Study Topline Results of FASN Inhibitor ASC40 for Treatment of Acne at EADV Congress 2023
Ascletis Pharma Inc. (HKEX:1672, “Ascletis”) today announces the poster presentation of Phase II study topline results of ASC40, a first-in-class fatty acid synthase (FASN) inhibitor for treatment of acne, at the European Academy of Dermatology and Venereology (EADV) Congress 2023 in Berlin, Germany.
October 10, 2023
·
4 min read
Drug Development
Ascletis Announces Positive Interim Data from the Phase IIb Expansion Cohort of ASC22 (Envafolimab) for Chronic Hepatitis B Functional Cure
Ascletis Pharma Inc. (HKEX: 1672, “Ascletis”) today announces positive interim data from the Phase IIb expansion cohort (the “Expansion Cohort”) of subcutaneously administered PD-L1 antibody ASC22 (Envafolimab) for functional cure of chronic hepatitis B (CHB).
September 28, 2023
·
2 min read
1 of 68,792
Next
